QGEN · Qiagen N.V. · Investor Relations

Partnership with Hamburg Trading Corp to advance applied testing and life science research Serving as a learning hub to empower the next generation of Filipino scientists through hands-on access to molecular workflows Facility designed to remove logistical barriers for researchers, enabling on-site evaluation without the need for internal equipment clearances Singapore, Singapore, July 7, 2026 – QIAGEN, a global provider of Sample to Insight solutions, has officially commenced a new distribution partnership with Hamburg Trading Corporation (Hamburg) for its life sciences business in the Philippines. This collaboration is anchored by the opening of the QIAGEN Experience Lab in the Philippines, a dedicated space designed to bring advanced molecular solutions directly to the local scientific community. As a cornerstone of this partnership, QIAGEN and Hamburg have unveiled a dedicated QIAGEN demo lab in the Philippines. This new facility represents a significant milestone in QIAGEN’s

QIAstat-Dx Meningitis/Encephalitis Panel enables detection of 16 pathogens from a single CSF sample , aligned with World Health Organization (WHO) recommendation This is the third QIAstat-Dx panel in the Australian Register of Therapeutic Goods (ARTG), now offering menu with tests for respiratory, gastrointestinal and central nervous system infections QIAstat-Dx delivers results in about one hour with real-time PCR, ensuring rapid and accurate results to support clinical decision-making Melbourne, Australia, June 15, 2026 - QIAGEN today announced that its QIAstat-Dx Meningitis/Encephalitis (ME) Panel has been included in the Australian Register of Therapeutic Goods (ARTG). The inclusion marks rapid molecular testing for the detection of pathogens associated with central nervous system (CNS) infections, supporting timely clinical decision-making in acute care settings. The QIAstat-Dx ME Panel enables fast detection of 16 common bacterial, viral and fungal pathogens using multiplex PCR